Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
Finding money to pay off debt can be challenging. Explore creative ways to boost your finances and eliminate debt faster.
22,001 articlesTwo top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
Myrtle Beach remains a top coastally located retirement pick, but real costs now require careful planning. Housing, i...
A longtime bitcoin advocate says MicroStrategy is a leveraged proxy for Bitcoin, and could trade at $1,000 per share ...
Oracle stock falling has investors weighing AI bets against near-term headwinds. This guide breaks down the drivers, ...
A prominent market observer says Strategy may have to liquidate more than 50,000 BTC by 2028 to cover obligations, si...
AI-driven data centers are reshaping memory supply. This article breaks down what data centers will consume for memor...
Bank of America Securities projects a new post-crisis peak for non-QM originations in 2026, driven by DSCR and invest...
SK Hynix is lining up a U.S. listing on Nasdaq, aiming to raise about $28 billion as memory chips ride AI demand and ...
Global worker engagement remains stuck near crisis levels, even as AI and remote work reshape the office. This story ...
Retirees are tilting funds toward a select group of Dividend Kings with multi-decade dividend raises and yields well ...
January CPI shows inflation cooled a notch but remains elevated, keeping policy expectations in focus and households ...
KBR faced a two-sided story: a massive backlog that hints at strong future demand, and a prominent investor trimming ...